Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce

  • Aligos Therapeutics Inc ALGS announced a portfolio reprioritization, with priorities focused on the rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs.
  •  The company also plans to maintain its ongoing NASH oligonucleotide research collaborations with Merck & Co Inc MRK
  • Additionally, the company plans to complete the ≤48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.
  • Also Read: Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud.
  • The reorganization comes with a layoff of around 10% of its staff to extend its cash resources through the end of 2024.
  • In all, there's been a 25% reduction in the overall workforce at Aligos since the beginning of 2022.
  • The company has already initiated Phase 2-enabling activities for the NASH program, including GLP toxicology studies, and it is planning a Phase 2 filing by the end of 2023.
  • COVID-19 program, ALG-097558, is expected to complete Phase 1-enabling activities in H1 2023. The company aims to complete a Phase 1 study evaluating single and multiple ascending doses in healthy volunteers in H2 2023 to enable the start of a Phase 2 study by the end of 2023.
  • Price Action: ALGS shares are down 1.15% at $1.8386 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!